| Summary of results of operations by segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | (In thousands) | | 2026 | | 2025 | | 2026 | | 2025 | Contract research | | $ | 356 | | $ | 442 | | $ | 893 | | $ | 887 | Licensing revenue | | | 1,273 | | | 1,335 | | | 2,732 | | | 2,345 | Total revenue | | | 1,629 | | | 1,777 | | | 3,625 | | | 3,232 | Cost of revenue | | | 218 | | | 515 | | | 613 | | | 1,021 | Research and development: | | | | | | | | | | | | | Bosakitug | | | 3,335 | | | 2,847 | | | 6,476 | | | 6,231 | ATI-052 | | | 4,899 | | | 1,418 | | | 8,080 | | | 2,037 | Modzatinib | | | 370 | | | 1,118 | | | 861 | | | 2,926 | ATI-9494 | | | 3,056 | | | 871 | | | 5,281 | | | 1,549 | Discovery | | | 1,972 | | | 749 | | | 3,411 | | | 1,417 | Total research and development project expense(1) | | | 13,632 | | | 7,003 | | | 24,109 | | | 14,160 | Personnel | | | 3,036 | | | 2,984 | | | 6,317 | | | 5,911 | Other research and development(2) | | | 1,398 | | | 1,462 | | | 3,297 | | | 2,962 | Total research and development | | | 18,066 | | | 11,449 | | | 33,723 | | | 23,033 | General and administrative(3) | | | 6,048 | | | 5,386 | | | 12,791 | | | 11,525 | Licensing | | | 1,235 | | | 1,335 | | | 2,628 | | | 2,345 | Revaluation of contingent consideration | | | 300 | | | 1,500 | | | 300 | | | 1,800 | Segment operating loss | | $ | (24,238) | | $ | (18,408) | | $ | (46,430) | | $ | (36,492) | Other income | | | 2,733 | | | 2,979 | | | 5,101 | | | 5,978 | Segment loss before income taxes | | $ | (21,505) | | $ | (15,429) | | $ | (41,329) | | $ | (30,514) |
| (1) | Research and development expenses primarily consist of direct costs incurred to specific programs, including costs to conduct clinical trials and to manufacture clinical drug supply. |
| (2) | Other research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, as well as stock-based compensation. |
| (3) | General and administrative expenses consist principally of salaries and related costs, including stock-based compensation, for personnel in executive, administrative, finance and legal functions, as well as facility-related costs, professional fees, business development costs, insurance costs, and travel expenses. |
|